PMID- 19053536
OWN - NLM
STAT- MEDLINE
DCOM- 20090323
LR  - 20220318
IS  - 1543-8384 (Print)
IS  - 1543-8392 (Electronic)
IS  - 1543-8384 (Linking)
VI  - 6
IP  - 1
DP  - 2009 Jan-Feb
TI  - Controlled surface modification with poly(ethylene)glycol enhances diffusion of 
      PLGA nanoparticles in human cervical mucus.
PG  - 173-81
LID - 10.1021/mp8001254 [doi]
AB  - Drug delivery to mucosal epithelia is severely limited by the mucus gel, which is 
      a physical diffusion barrier as well as an enzymatic barrier in some sites. 
      Loading of drug into polymer particles can protect drugs from degradation and 
      enhance their stability. To improve efficacy of nanoparticulate drug carriers, it 
      has been speculated that polymers such as poly(ethylene)glycol (PEG) incorporated 
      on the particle surface will enhance transport in mucus. In the present study, we 
      demonstrate the direct influence of PEG on surface properties of 
      poly(lactic-co-glycolic)acid (PLGA) nanoparticles (d = 170 +/- 57 nm). PEG of 
      various molecular weights (MW = 2, 5, 10 kDa) were incorporated at a range of 
      densities from 5-100% on the particle surface. Our results indicate PEG addition 
      improves dispersion, neutralize charge, and enhance particle diffusion in 
      cervical mucus in a manner strongly dependent on polymer MW and density. 
      Diffusion of PEGylated particles was 3-10x higher than that of unmodified PLGA 
      particles. These findings improve the understanding of, and confirm a possible 
      direction for, the rational design of effective carriers for mucosal drug/vaccine 
      delivery.
FAU - Cu, Yen
AU  - Cu Y
AD  - Department of Biomedical Engineering, Yale University, New Haven, Connecticut 
      06511, USA.
FAU - Saltzman, W Mark
AU  - Saltzman WM
LA  - eng
GR  - R01 EB000487-15/EB/NIBIB NIH HHS/United States
GR  - R56 EB000487-18A1/EB/NIBIB NIH HHS/United States
GR  - R01 EB000487-17/EB/NIBIB NIH HHS/United States
GR  - R01 EB000487-13/EB/NIBIB NIH HHS/United States
GR  - R01 EB000487/EB/NIBIB NIH HHS/United States
GR  - R01 EB000487-14/EB/NIBIB NIH HHS/United States
GR  - R56 EB000487/EB/NIBIB NIH HHS/United States
GR  - R01 EB000487-16/EB/NIBIB NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PL  - United States
TA  - Mol Pharm
JT  - Molecular pharmaceutics
JID - 101197791
RN  - 059QF0KO0R (Water)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - 3WJQ0SDW1A (Polyethylene Glycols)
SB  - IM
MH  - Cervix Mucus/*metabolism
MH  - Diffusion
MH  - Humans
MH  - Lactic Acid/*chemistry/*metabolism
MH  - Microscopy, Electron, Scanning
MH  - Nanoparticles/*chemistry/ultrastructure
MH  - Polyethylene Glycols/*chemistry
MH  - Polyglycolic Acid/*chemistry/*metabolism
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
MH  - Surface Properties
MH  - Water
PMC - PMC2637413
MID - NIHMS86566
EDAT- 2008/12/05 09:00
MHDA- 2009/03/24 09:00
PMCR- 2010/01/01
CRDT- 2008/12/05 09:00
PHST- 2008/12/05 09:00 [pubmed]
PHST- 2009/03/24 09:00 [medline]
PHST- 2008/12/05 09:00 [entrez]
PHST- 2010/01/01 00:00 [pmc-release]
AID - 10.1021/mp8001254 [pii]
AID - 10.1021/mp8001254 [doi]
PST - ppublish
SO  - Mol Pharm. 2009 Jan-Feb;6(1):173-81. doi: 10.1021/mp8001254.